What is Osmind, Inc.?
Founded in 2020 and headquartered in San Francisco, Osmind, Inc. operates at the intersection of healthcare technology and clinical innovation. The company provides a comprehensive software platform designed to support mental health clinicians, particularly those administering FDA-approved treatments such as ketamine and esketamine. Furthermore, the organization is actively facilitating the integration of emerging clinical trials for MDMA and psilocybin into standard care workflows. By providing a centralized, data-driven environment, Osmind enables providers to track patient outcomes, manage regulatory compliance, and optimize treatment protocols in real-time. This focus on high-acuity mental health care has established the firm as a vital partner for clinics seeking to modernize their service delivery models while maintaining rigorous clinical standards.
How much funding has Osmind, Inc. raised?
Osmind, Inc. has raised a total of $57M across 3 funding rounds:
Angel/Seed
$2M
Series A
$15M
Series B
$40M
Angel/Seed (2020): $2M with participation from What If Ventures, 20|20 Fund, General Catalyst Partners, and Jeffrey Leiden MD
Series A (2021): $15M led by Offline Ventures, AME Cloud Ventures, Tiger Global, General Catalyst, and Future Ventures
Series B (2022): $40M supported by DFJ Growth
Key Investors in Osmind, Inc.
General Catalyst
General Catalyst is a venture capital firm that identifies and supports transformational business opportunities across multiple sectors, including healthcare and enterprise software, by providing operational expertise and strategic guidance.
DFJ Growth
DFJ Growth is a late-stage global venture capital firm that provides capital to companies in seed, early, and growth-stages, focusing on technology companies poised for market leadership.
AME Cloud Ventures
AME Cloud Ventures is a venture fund led by Jerry Yang that focuses on seed to later stage companies building infrastructure and value chains around data, particularly in the technology-heavy sector.
What's next for Osmind, Inc.?
With the infusion of its latest capital, Osmind is poised to accelerate its market penetration and expand its technological capabilities. The strategic roadmap likely involves deepening its data analytics infrastructure to provide more granular insights into treatment efficacy, which is essential for the broader adoption of psychedelic medicine. As the regulatory landscape for these innovative therapies continues to evolve, Osmind's ability to provide a compliant, scalable, and user-friendly platform will be a key differentiator. The company is expected to focus on scaling its enterprise partnerships, enhancing its clinical decision support tools, and potentially exploring new therapeutic verticals that require specialized data management. By maintaining its commitment to evidence-based care, Osmind is well-positioned to lead the digital transformation of the psychiatric industry.
See full Osmind, Inc. company page
